ALIVUS ALIVUS LIFE SCIENCES LTD
Healthcare
LTP
1,480.6
CHG · %
-16.6 (-1.11%)
VOL · TODAY
15.82L
PREV CLOSE
1,497.2
Today's range1,403.4 · 1,523.2
1,480.6
52-week range819 · 1,529
1,480.6
Loading candles…
Alivus Life Sciences Ltd., formerly Glenmark Life Sciences Ltd., is a pharmaceutical and chemical manufacturing company specializing in the development and production of select high-value, non-commoditized active pharmaceutical ingredients (APIs) focused on chronic therapeutic areas such as cardiovascular disease, central nervous system disorders, pain management, and diabetes. The company operates in two main segments: manufacturing APIs and providing contract development and manufacturing services to specialty pharmaceutical companies. With over 700 customers globally, Alivus serves markets in North America, Europe, Japan, and more than 75 countries worldwide. It is a subsidiary of Nirma Limited, a diversified conglomerate involved in consumer products, cement, chemicals, and pharmaceuticals. In early 2024, Alivus transitioned to new ownership under Nirma Limited, moving from its previous status as a captive entity under Glenmark Pharmaceuticals to an independent global company.
ALIVUS is not part of any active scan today.
This page is a live market overview for ALIVUS LIFE SCIENCES LTD (ALIVUS) on the NSE. As a listed security, ALIVUS LIFE SCIENCES LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for ALIVUS before placing trades on tick2trade.
As of the latest feed, ALIVUS last traded at ₹1,480.6 on NSE, down ₹16.6 (1.11%) from the previous close of ₹1,497.2. Today's session range is ₹1,403.4 – ₹1,523.2, against a 52-week band of ₹819 – ₹1,529. Traded volume today stands at 15.82L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for ALIVUS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether ALIVUS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for ALIVUS LIFE SCIENCES LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in ALIVUS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated ALIVUS option chain page linked from this overview.
// similar in healthcare326 total